Krishna Institute of Medical Sciences

675.95
+3.05
(0.45%)
Market Cap
27,047.39 Cr
EPS
38.75
PE Ratio
71.59
Dividend Yield
0.00 %
52 Week High
708.00
52 Week Low
350.00
PB Ratio
12.61
Debt to Equity
0.58
Sector
Hospitals
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from9 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+88.89 %
+88.89 %
Hold
Hold+11.11 %
+11.11 %
Sell
Sell0.0 %
0.0 %
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,170.00
#1 1,13,740.62
101.05
5,584.10
18.77
#1 1,058
26.84
57.57
7,095.00
1,02,015.21
77.51
#1 19,165.50
14.74
917
49.14
57.82
721.00
54,432.48
64.11
6,931.20
8.99
645
-7.43
61.88
1,740.00
35,558.78
#1 44.96
5,093.40
10.96
790
3.41
44.82
1,211.10
32,528.62
63.13
2,759.20
#1 25.09
326
-20.35
51.90
553.20
27,633.06
74.55
3,723.70
22.85
205
#1 3,986.36
56.75
675.95
#7 27,047.39
#6 71.59
#7 2,511.20
#7 12.94
#5 336
#3 48.39
60.33
1,352.30
13,732.83
57.70
1,334.00
10.76
218
10.57
45.37
1,480.00
9,703.77
49.50
1,095.50
21.32
177
-0.88
52.00
593.95
8,280.58
148.78
1,929.10
12.97
41
-71.06
55.43
Forecast
Actual
Growth Rate
Revenue Growth
12.94 %
Net Income Growth
-8.15 %
Cash Flow Change
20.60 %
ROE
-14.99 %
ROCE
-23.55 %
EBITDA Margin (Avg.)
-8.15 %

Quarterly Financial Results

Quarterly Financials
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Revenue
268
206
411
361
363
478
417
398
388
501
588
569
581
609
655
609
638
693
782
790
812
Expenses
203
165
268
268
258
330
283
264
259
358
412
411
413
449
475
459
475
509
559
585
599
EBITDA
65
40
143
93
105
148
134
134
129
143
177
158
168
160
180
150
163
184
223
205
213
Operating Profit %
24 %
18 %
34 %
26 %
28 %
30 %
31 %
33 %
31 %
28 %
27 %
27 %
28 %
26 %
27 %
24 %
25 %
26 %
28 %
24 %
25 %
Depreciation
17
17
16
20
17
17
18
19
19
29
31
33
35
32
33
35
46
39
41
45
53
Interest
10
9
7
9
7
6
3
3
4
6
8
12
5
9
9
12
16
18
20
26
27
Profit Before Tax
38
14
120
65
81
125
113
112
107
107
138
113
127
119
139
102
100
127
162
135
134
Tax
10
5
29
17
22
33
29
28
24
28
31
31
29
32
37
26
29
32
42
42
28
Net Profit
28
9
90
48
59
92
84
84
83
79
106
82
99
87
101
77
72
95
121
93
106
EPS in ₹
3.72
1.49
11.21
6.55
7.72
11.48
10.34
10.14
10.08
8.74
12.14
9.49
11.65
10.10
11.50
8.98
8.18
10.82
2.68
2.22
2.54

Balance Sheet

Balance Sheet
2018
2019
2020
2021
2022
2023
2024
Total Assets
958
1,118
1,196
1,436
1,907
2,941
3,852
Fixed Assets
755
863
916
931
1,005
1,766
2,434
Current Assets
156
174
220
451
393
478
547
Capital Work in Progress
0
0
2
9
21
477
600
Investments
0
0
0
0
333
68
157
Other Assets
203
254
278
496
549
630
661
Total Liabilities
958
1,118
1,196
1,436
1,907
2,941
3,852
Current Liabilities
749
201
219
278
215
297
452
Non Current Liabilities
347
351
366
282
282
707
1,307
Total Equity
-138
566
611
876
1,411
1,938
2,093
Reserve & Surplus
-209
466
523
786
1,307
1,590
1,748
Share Capital
50
75
75
78
80
80
80

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
5
-11
5
3
-3
33
12
-27
36
-15
Investing Activities
-71
-41
-100
-64
-110
-125
-354
-412
-416
-753
Operating Activities
64
95
82
106
134
202
356
324
432
521
Financing Activities
12
-66
24
-39
-27
-44
10
61
20
217

Share Holding

% Holding
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
38.84 %
38.84 %
38.84 %
38.84 %
38.84 %
38.84 %
38.84 %
38.84 %
38.84 %
38.84 %
38.82 %
38.82 %
38.82 %
38.82 %
38.82 %
38.82 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
8.61 %
8.61 %
0.00 %
14.25 %
0.00 %
16.73 %
17.84 %
15.85 %
15.68 %
15.45 %
DIIs
13.81 %
16.11 %
18.35 %
18.49 %
20.46 %
27.98 %
28.32 %
29.76 %
33.03 %
34.80 %
31.63 %
33.13 %
32.12 %
32.30 %
32.05 %
31.95 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
13.14 %
14.23 %
13.38 %
12.88 %
11.81 %
11.50 %
11.32 %
11.10 %
11.22 %
11.15 %
10.84 %
10.73 %
10.61 %
10.55 %
10.97 %
11.24 %
Others
34.21 %
30.82 %
29.42 %
29.79 %
28.88 %
21.68 %
12.92 %
11.69 %
16.91 %
0.96 %
18.70 %
0.59 %
0.61 %
2.48 %
2.48 %
2.54 %
No of Share Holders
0
267
86,389
74,355
73,664
70,795
67,735
60,980
65,449
66,957
71,014
69,092
69,063
77,617
95,468
1,01,895

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %

No dividends have been distributed by the company in the past 10 years

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
29 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
29 Aug 2025 635.00 673.65
12 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 May 2025 657.35 635.00
06 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
06 Feb 2025 606.05 649.15
09 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
09 Nov 2024 520.35 570.15
28 Jun 2024 SPLIT Split
2:10
13 Sept 2024 420.62 420.62
29 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
29 Aug 2024 389.93 502.38

Announcements

Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 13, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 12, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 12, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMay 12, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMay 12, 2025
Re-Appointment Of Mrs. Y. Prameela Rani As An Independent Director For The Further Period Of 5 Years W.E.F 19.05.2025.May 12, 2025
Appointment Of Secretarial Auditors And Appointment Of Cost Auditors.May 12, 2025
Results-Financial Result For The Quarter And Year Ended 31.03.2025May 12, 2025
Board Meeting Outcome for Outcome Of Board MeetingMay 12, 2025
Board Meeting Intimation for KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED Has Informed The Exchange About Board Meeting To Be Held On 12-May-2025 To Inter-Alia Consider And Approve The Audited Financial Results Of The Company For The Yearly Ended March 2May 02, 2025
KIMS : Krishna Institute Of Medical Sciences Limited Has Informed Regarding Receipt Of Approval Under Regulation 31A Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Apr 28, 2025
Closure of Trading WindowMar 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 19, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 10, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 05, 2025
Krishna Institute Of Medical Sciences Limited Has Informed The Exchange About Intimation Of The Order Received From The Regional Director (South-East Region) Confirming The Scheme Of Amalgamation U/S 233 Of Companies Act 2013 For The Merger Of RajyalakshmMar 02, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 22, 2025
KIMS Entered Into An Operations And Management Agreement With Splendid Hospitals Private Limited Hyderabad Telangana.Feb 20, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 17, 2025
KIMS Entered Into An Operations And Management Agreement With Ushahkal Abhinav Institute Of Medical Sciences (UAIMS Hospital) Sangli Maharashtra.Feb 17, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 15, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 15, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 14, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 07, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 07, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 06, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 06, 2025
Integrated Filing (Financial)Feb 06, 2025
Quarterly Result_31St December 2024Feb 06, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On 06â„¢ February 2025 Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Feb 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 31, 2025
KIMS Swastha Private Limited (The KIMS) A Wholly-Owned Subsidiary Of Krishna Institute Of Medical Sciences Limited Has Entered Into An Agreement On 27Th January 2025 With Valiyath Institute Of MedicalJan 28, 2025
Board Meeting Intimation for The Approval Of The Unaudited (Standalone & Consolidated) Financial Results Of The Company For The 03Rd Quarter And Nine Months Ended December 31 2024Jan 27, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 08, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 08, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 07, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 01, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 10, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 07, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 06, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 06, 2024
Announcement under Regulation 30 (LODR)-AcquisitionDec 05, 2024
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerNov 29, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 29, 2024

Technical Indicators

RSI(14)
Neutral
60.33
ATR(14)
Less Volatile
24.15
STOCH(9,6)
Neutral
71.21
STOCH RSI(14)
Overbought
96.20
MACD(12,26)
Bullish
0.04
ADX(14)
Weak Trend
13.63
UO(9)
Bearish
62.94
ROC(12)
Uptrend And Accelerating
4.53
WillR(14)
Overbought
-15.89

About Krishna Institute of Medical Sciences

Krishna Institute of Medical Sciences Limited (KIMS) is an Indian healthcare company operating 12 multispecialty hospitals under the KIMS Hospitals brand. With over 4,000 beds, KIMS provides tertiary and quaternary healthcare services across more than 40 specialties and super specialties. The company's network includes hospitals in Telangana, Andhra Pradesh, and Maharashtra. KIMS offers medical education programs through affiliations with state medical boards and universities. The company's hospitals are equipped with advanced medical technology, including robotic surgical systems and specialized imaging equipment. KIMS has received various accreditations and awards for its healthcare services and facilities. In recent developments, Sunshine Hospitals became a subsidiary of KIMS in 2022, and the company opened a new gastroenterology unit in Vizag.
Listing Date
28 Jun, 2021(3 Years, 28 days)
Chairperson NameBhaskara Rao Bollineni